Table 3.
Estimates of LVX Cmax and AUC0-24 in sputum of CF patients expressed as a number of times those were calculated in the serum obtained from the phase 2 and phase 3 clinical studies.
| Clinical Study | LVX Sputum Versus Serum Cmax | LVX Sputum Versus Serum AUC0-24 |
|---|---|---|
| MPEX-204 | 5000 to 7000-fold higher in sputum than in serum | 300-fold higher in sputum than in serum |
| MPEX-207 | 3500-fold higher in sputum than in serum | 400-fold higher in sputum than in serum |
| MPEX-209 | 1700-fold higher in sputum than in serum | 600-fold higher in sputum than in serum |